Genmab — April 2025
-
Genmab A/S Share Capital Reduction.. hvad er jeres holdning/erfaring med dette?
-
article in Blood - Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial https://ashpublications.org/blood/article/doi/10.1182/blood.2024026830/535030/Epcoritamab-plus-GemOx-in-transplant-ineligible
-
Novartis follows Lilly and J&J in announcing multibillion-dollar US manufacturing investment -
With US tariffs on pharmaceuticals likely to come "very soon," another of the world's largest drugmakers is announcing plans to beef up their American manufacturing. -
On Thursday, Swiss-based Novartis said it would invest $23 billion in American manufacturing and R&D over the next five years. It follows similar moves this year by Indianapolis-based Eli Lilly and New Jersey-headquartered Johnson & Johnson.
-
As part of Novartis' investment, which includes seven new facilities, the company said it will be able to make all of its "key" medicines "end-to-end" in the US. It wasn't immediately clear how the company was defining "key" drugs, and if that meant some medicines it sells in the US will still be manufactured elsewhere.
-
Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects https://jitc.bmj.com/content/13/4/e011377
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind